Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT07511972 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study terminated by Sponsor

Conditions

CRC

Interventions

DRUG: NGM707 plus pembrolizumab

Sponsor

NGM Biopharmaceuticals, Inc